Welcome to our dedicated page for Phio Pharmaceuticals news (Ticker: PHIO), a resource for investors and traders seeking the latest updates and insights on Phio Pharmaceuticals stock.
Phio Pharmaceuticals Corp (NASDAQ: PHIO) is a clinical-stage biotechnology pioneer developing next-generation immuno-oncology therapies using its proprietary INTASYL® RNAi platform. This page provides centralized access to official press releases, clinical trial updates, and strategic partnership announcements related to PHIO's innovative approach to enhancing immune cell function against cancer.
Investors and researchers will find timely updates on PHIO's progress in silencing immune checkpoint targets like PD-1 and TIGIT through its self-delivering siRNA technology. The resource covers key developments including clinical trial milestones, collaborative research findings, and regulatory advancements for therapies like lead candidate PH-762.
Content spans multiple categories essential for tracking biopharmaceutical innovation: clinical trial results, research collaborations with institutions like Gustave Roussy, intellectual property updates, and technology licensing agreements. Each update is sourced directly from company disclosures to ensure reliability.
Bookmark this page for streamlined monitoring of PHIO's advancements in RNAi-based cancer therapeutics. Check regularly for new developments in their mission to overcome tumor-induced immunosuppression through precision gene silencing.
Phio Pharmaceuticals (NASDAQ: PHIO) announced positive safety results for the third cohort in its Phase 1b clinical trial of PH-762, their lead INTASYL® siRNA compound for skin cancer treatment. The Safety Monitoring Committee recommended advancing to the fourth dose escalation cohort following successful results in three cutaneous squamous cell carcinoma patients, who showed no serious adverse events or dose-limiting toxicities.
The multi-center trial (NCT 06014086) evaluates PH-762's safety and tolerability in cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. Prior results from cohorts 1 and 2, comprising seven patients, showed promising outcomes. In the second cohort, two patients achieved complete response (100% tumor clearance) and one patient showed partial response (90% clearance) by Day 36. All three patients in cohort 1 and one patient in cohort 2 maintained stable disease.
Phio Pharmaceuticals (NASDAQ: PHIO) announced two podium presentations at the 11th Annual Immunotherapy of Cancer Conference in Munich, Germany on April 3, 2025. The presentations focus on their lead INTASYL siRNA product candidates:
1. PH-762: An INTASYL siRNA compound targeting PD-1, currently in clinical trials (NCT 06014086) as a neoadjuvant intratumoral therapy for cutaneous malignancies. The therapy has shown promising preclinical efficacy and favorable tolerability.
2. PH-894: An INTASYL siRNA compound that selectively silences BRD4, enhancing NK cell activation and proliferation without off-target effects, aimed at improving adoptive cell therapy.
The presentations will be delivered by Melissa Maxwell, Phio's Director of Research and Program Management, in Plenary Sessions 3 and 11 on April 3rd and 5th, 2025, respectively.
Phio Pharmaceuticals (NASDAQ: PHIO) reported its 2024 financial results and provided updates on its PH-762 clinical trial progress. The company's Phase 1b trial for PH-762, treating cutaneous carcinomas through intratumoral injection, showed promising results with 2 complete responses and 1 partial response in the second cohort. The third cohort is fully enrolled, with study completion expected in Q3 2025.
Financial highlights include raising $9.2 million through offerings and $2.9 million from warrant exercises. The company reported cash position of $5.4 million as of December 31, 2024, with net loss decreasing to $7.2 million ($9.08 per share) from $10.8 million in 2023. Research and development expenses decreased by 42% to $2.7 million, while general and administrative expenses reduced by 14% to $3.7 million.
The company implemented cost rationalization measures, including relocating to a smaller facility and terminating its Clinical Co-Development Agreement with AgonOx. Phio's patent portfolio includes 77 issued patents, with 69 covering its INTASYL technology.
Phio Pharmaceuticals (NASDAQ: PHIO) presented interim results from its Phase 1b clinical study of PH-762 at the American Academy of Dermatology's Late-Breaking Research session. The study evaluates the safety and tolerability of intratumoral PH-762 in cutaneous carcinomas.
In the second dose cohort of four patients, two patients with cutaneous squamous cell carcinoma (cSCC) achieved complete response (100% pathological cure), one achieved partial response (90% pathological cure), and one showed stable disease. The study has completed required safety enrollment for its third dose cohort, with the fourth dose cohort screening planned for early April.
PH-762 utilizes INTASYL® siRNA gene silencing technology to enhance immune cells' effectiveness in killing cancer cells. The research focuses on cSCC, melanoma, and Merkel cell carcinoma, with stages 1 and 2 cSCC representing 77% of all new cSCC cases annually.
Phio Pharmaceuticals (NASDAQ: PHIO) has completed enrollment for the third safety cohort in its Phase 1b dose-escalation clinical trial of PH-762. The study (NCT 06014086) is evaluating the intratumoral administration of PH-762 as a neoadjuvant treatment for various skin cancers, including cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.
The multi-center trial aims to assess safety, tolerability, and tumor response while determining the recommended dose for future studies. The company utilizes its proprietary INTASYL® siRNA gene silencing technology to enhance the effectiveness of immune cells in targeting cancer cells. Phio plans to begin screening for the fourth dose cohort in early April 2025.
Phio Pharmaceuticals (NASDAQ: PHIO) has announced its participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series. The event will feature CEO and Chairman Robert Bitterman presenting the company's proprietary INTASYL siRNA technology and ongoing clinical trial of PH-762 for skin cancer treatment.
The presentation and live Q&A session is scheduled for March 5, 2025, at 12:00 pm EST. The virtual event will be accessible to stakeholders, investors, and interested parties, with a replay available on the Renmark Financial Communications website.
Phio Pharmaceuticals (NASDAQ: PHIO), a clinical-stage biotechnology company developing INTASYL® siRNA gene silencing technology for cancer treatment, has appointed David H. Deming to its Board of Directors effective February 19, 2025. Deming will serve on the Board's Nominating Committee, bringing the total board membership to 6 directors, with 5 being independent.
Deming brings over 30 years of experience in investment banking and asset management, including 27 years at JP Morgan where he led the Health Group in investment banking for 12 years. He later joined Integrated Finance , where he developed the SmartNest 401(k) asset allocation product, which was subsequently acquired by Dimensional Fund Advisors in 2010.
Phio Pharmaceuticals (NASDAQ: PHIO) announced its participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series. The company's CEO and Chairman, Robert Bitterman, will present on February 4, 2025, at 2:00 pm EST, discussing their INTASYL siRNA technology and ongoing clinical trial of PH-762 for skin cancer treatment.
The presentation will include a live Q&A session, with a replay available on Renmark Financial Communications' website. Phio is a clinical-stage biotechnology company developing therapeutics using their INTASYL siRNA gene silencing technology, aimed at enhancing immune cells' effectiveness in fighting cancer cells.
Phio Pharmaceuticals (NASDAQ: PHIO), a clinical-stage biotechnology company, has announced its participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series scheduled for January 29, 2025, at 2:00 pm EST.
During the presentation, Robert Bitterman, CEO and Chairman of the Board, will showcase the company's proprietary INTASYL siRNA technology and provide updates on their ongoing clinical trial of PH-762 for treating skin cancers. The INTASYL technology is designed to enhance the effectiveness of immune cells in fighting cancer cells.
Stakeholders, investors, and interested parties are invited to attend this live virtual event. A replay will be available on the Renmark Financial Communications website. Participants are advised to use the latest version of Google Chrome for optimal connectivity.
Phio Pharmaceuticals (NASDAQ: PHIO) has closed a $1.83 million registered direct offering of 610,000 common shares at $3.00 per share, along with concurrent private placement warrants for 1,220,000 shares at $3.00 exercise price, expiring in 24 months. Since December 2024, the company has raised total gross proceeds of approximately $12.08 million, including $9.15 million from offerings and $2.9 million from warrant exercises.
The funds will support working capital and development costs for PH-762's Phase 1b clinical trial treating cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. Additionally, proceeds will advance development of PH-894, targeting BRD4 protein in solid tumors. H.C. Wainwright & Co. served as the exclusive placement agent for the offering.
